#4-100E. Precision Stratification: The Causal Role of IFN-α in Sjögren's Disease (Lancet Rheumatol, 2026)

Can we redefine the treatment landscape for treatment-resistant Sjögren’s disease by identifying its underlying immune endotypes? In today's episode, we examine a pivotal study investigating the role of interferon-alpha (IFN-α) in driving specific Sjögren's disease endotypes. Utilizing ultrasensitive single-molecule ELISA and Olink proteomics on the UKPSSR and UK Biobank cohorts, researchers discovered that oligoprotein IFN signatures can be detected up to 14 years prior to a formal diagnosis. The most groundbreaking finding is the demonstration, via a novel transgenic mouse model, that chronic systemic elevation of IFN-α is a direct causal driver of a distinct immune endotype characterized by TRIM21 autoantibodies, rather than a mere epiphenomenon. However, when critically appraising this study, we must consider that approximately 40% of patients do not exhibit elevated IFN-α, leaving the immunopathology of this substantial subgroup largely unaddressed and emphasizing the need for further non-IFN pathway discoveries. For clinicians, this highlights an urgent paradigm shift toward precision medicine; embracing these high-resolution biomarkers allows for precise immunological stratification, paving the way for targeted therapeutic trials—such as IFNAR1 blockade—and the preclinical identification of at-risk patients in our daily practice.

Citation: Forbes D., Behrendt R., Hunt D., et al. Interferon-α as a precision medicine tool in Sjögren’s disease: a cohort and experimental medicine study. The Lancet Rheumatology. 2026. DOI: 10.1016/S2665-9913(26)00038-X

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.